Answers are grounded in this paper and cite their sources.
Investigation reports three-dose BNT162b2 immunogenicity against the omicron variant in patients with MASLD, highlighting metabolic impacts on viral protection.
We aimed to investigate the effect of metabolic dysfunction-associated steatotic liver disease (MASLD) on three-dose BNT162b2 immunogenicity to the omicron variant.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: